At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Prasinezumab (drug), Placebo (drug)
- How long the study runs
- Study runs about 67 months (dates as stated)
- About the drug or intervention
- Prasinezumab — drug: Participants will receive Prasinezumab as an IV Infusion as per the schedule mentioned in the protocol. · Placebo — drug: Participants will receive Placebo as an IV Infusion per the schedule mentioned in the protocol
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 50 Years to 85 Years
- Who
- All
- Number of participants
- 900
- Started
- 2025-11-24
- Last checked
- 2026-10
Plain English Summary
What is this study?
- • Testing a new treatment for parkinson's disease
- • Phase3 - 900 participants
- • The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa
Who can take part?
- • Ages 50 Years to 85 Years
- • Diagnosed with parkinson's disease
Where?
- • Dundee - Ninewells Hospital, Dundee- Scotland
- • Exeter - Royal Devon and Exeter Hospital (Wonford)
- • London - Royal London Hospital
- • London - Charing Cross Hospital
- • +3 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 50 Years - 85 Years
- Who can join: All genders
What the study is looking for
- ✓Body weight within 40-110 kilograms (kg) (88-242 pounds \[lbs\]) and a body mass index within the range 18-34 kg/m2
- ✓Diagnosis of idiopathic PD based on Movement Disorder Society (MDS) criteria
- ✓Has received monotherapy treatment
- ✓An MDS-UPDRS Part IV score of 0 at screening and prior to randomization
- ✓Hoehn and Yahr (H\&Y) Stage 1 or 2 off medication at screening and prior to randomization
Who cannot take part
- ✗Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which...
- ✗Medical history indicating a parkinsonian syndrome other than idiopathic PD
- ✗Diagnosis of a significant neurologic disease other than PD
- ✗Chronic uncontrolled hypertension
See the full criteria
Where Is This Study? (7 UK sites)
Ninewells Hospital, Dundee- Scotland
Dundee DD2 1SY, United Kingdom
Royal Devon and Exeter Hospital (Wonford)
Exeter EX2 5DW, United Kingdom
Royal London Hospital
London E1 1FR, United Kingdom
Charing Cross Hospital
London W6 8RF, United Kingdom
Campus for Ageing and Vitality
Newcastle NE4 5PL, United Kingdom
Oxford University Hospitals NHS Foundation Trust
Oxford OX3 7LE, United Kingdom
Plymouth Hospitals NHS Trust - Derriford Hospital
Plymouth,Devon PL6 8DH, United Kingdom
How to Get in Touch
Reference Study ID Number: BN44715 https://forpatients.roche.com/ No attachments to email below.
Sponsor contactCONTACT
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Sponsor contactCONTACT